AnaMar Medical raises SEK 75 million in new financing
The Swedish biotech company AnaMar Medical raises SEK 75 millon in a rights issue to finance continued development of its projects in chronic joint diseases. In a first step, the funds will finance a phase I study of a drug candidate developed for rheumatoid arthritis.”We are happy to have successfully secured SEK 75 million in new financing in the current financial climate. It’s an acknowledgement that our principal owner shares our confidence in our projects. With this financing in place, we can take the first step into the clinic,” says AnaMar’s CEO Owe Gårlin. “First in line is a